The vanilloid receptor TRPV1 has been identified as a molecular target for the treatment of pain associated with inflammatory diseases and cancer. AMG 517 is a potent and selective transient receptor potential vanilloid-1 (TRPV1) antagonist. AMG 517 was selected as a second-generation candidate for further evaluation in human clinical trials as a potential new treatment for chronic pain.

June 21, 2017

prudect name : The vanilloid receptor TRPV1 has been identified as a molecular target for the treatment of pain associated with inflammatory diseases and cancer. AMG 517 is a potent and selective transient receptor potential vanilloid-1 (TRPV1) antagonist. AMG 517 was selected as a second-generation candidate for further evaluation in human clinical trials as a potential new treatment for chronic pain.
AMG 517

Synonyms: CAS NO: 659730-32-2Molecular Formula: C₂₀H₁₃F₃N₄O₂SMolecular Weight: 430.4Purity: 98% minSolubility: In DMSOStorage: -20°C

941678-49-5 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18497825